Association of TLR2 and TLR4 gene polymorphism with susceptibility to wart infections and their response to candida antigen immunotherapy

References

• Kasim K, Amer S, Mosaad M, et al. Some epidemiologic aspects of common warts in rural primary school children. ISRN Epidemiol. 2013;2013. Article ID 283591.
   Google Scholar
• Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401:70–79.
   PubMed Web of Science ®Google Scholar
• Bruggink SC, Waagmeester SC, Gussekloo J, et al. Current choices in the treatment of cutaneous warts: a survey among Dutch GP. Fam Pract. 2010;27:549–553.
   PubMed Web of Science ®Google Scholar
• Kollipara R, Ekhlassi E, Downing C, et al. Advancements in pharmacotherapy for noncancerous manifestations of HPV. J Clin Med. 2015;4:832–846.
   PubMed Web of Science ®Google Scholar
• Aldahan AS, Mlacker S, Shah VV, et al. Efficacy of intralesional immunotherapy for the treatment of warts: a review of the literature. Dermatol Ther. 2016;29:197–207.
   PubMed Web of Science ®Google Scholar
• Chandrashekar L. Intralesional immunotherapy for the management of warts. Indian J Dermatol Venereol Leprol. 2011;77:261.
   PubMed Web of Science ®Google Scholar
• Yang X, Cheng Y, Li C. The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Ther. 2017;2:17055.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhu K, Cheng H. Toll like receptors in human papillomavirus infection. Arch Immunol Ther Exp. 2013;61:203–215.
   PubMed Web of Science ®Google Scholar
• Misch EA, Hawn TR. Toll like receptor polymorphisms and susceptibility to human disease. Clin Sci. 2008;114:347–360.
   PubMed Web of Science ®Google Scholar
• Pandey S, Mittal RD, Srivastava M, et al. Impact of Toll-like receptors 2 (–196 to –174 del) and TLR4 (Asp299GLY,Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol Oncol. 2009;114:501–505.
   PubMed Web of Science ®Google Scholar
• Horn TD, Johnson SM, Helm RM, et al. Intralesional immunotherapy of warts with mumps, Candida and Trichophyton skin test antigens: a single-blinded, randomized and controlled trial. Arch Dermatol. 2005;141:589–594.
   PubMed Web of Science ®Google Scholar
• Ness T, Abdallah M, Adams J, et al. Candida albicans-derived mannoproteins activate NF-κB in reporter cells expressing TLR4, MD2 and CD14. PLoS One. 2017;12:e0189939.
   PubMed Web of Science ®Google Scholar
• Majid I, Imran S. Immunotherapy with intralesional Candida albicans antigen in resistant or recurrent warts: a study. Indian J Dermatol. 2013;58:360. ‏
   PubMedGoogle Scholar
• Lee YC, Kim C, Shim C, et al. Toll-like receptors 2 and 4 and their mutations in patients with otitis media and middle ear effusion. Clin Exp Otorhinolaryngol. 2008;1:189–195.
   PubMed Web of Science ®Google Scholar
• Hammad NM, ElBadawy NE, Nasr AM, et al. Mannose-binding lectin gene polymorphism and its association with susceptibility to recurrent vulvovaginal candidiasis. Bio Med Res Int. 2018;2018:7648152.
   Google Scholar
• Khurshid K, Ali U, Pal SS. Role of Candida antigen in treatment of viral warts: a placebo-controlled study. J Pak Assoc Dermatol. 2016;19:146–150. ‏
   Google Scholar
• Na CH, Choi H, Song SH, et al. Two year experience of using the measles, mumps and rubella vaccine as intralesional immunotherapy for warts. Clin Exp Dermatol. 2014;39:583–589.
   PubMed Web of Science ®Google Scholar
• Nofal A, Nofal E. Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol. 2010;24:1166–1170.
   PubMed Web of Science ®Google Scholar
• Kottke MD, Parker SR. Intravenous cidofovir-induced resolution of disfiguring cutaneous human papillomavirus infection. J Am Acad Dermatol. 2006;55:533–536. ‏
   PubMed Web of Science ®Google Scholar
• Phillips RC, Ruhl TS, Pfenninger JL, et al. Treatment of warts with Candida antigen injection. Arch Dermatol. 2000;136:1274–1275.‏
   PubMed Web of Science ®Google Scholar
• Bochud PY, Hersberger M, Taffé P, et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS. 2007;21:441–446.
   PubMed Web of Science ®Google Scholar
• Singh SK, Mohan A, Gupta AK, et al. A comparative study between intralesional PPD and vitamin D3 in treatment of viral warts. Int J Res Dermatol. 2018;4:197. ‏
   Google Scholar
• Nofal A, Marei A, Amer A, et al. Significance of interferon gamma in the prediction of successful therapy of common warts by intralesional injection of Candida antigen. Int J Dermatol. 2017;56:1003–1009. ‏
   PubMed Web of Science ®Google Scholar
• Ghadgepatil SS, Gupta S, Sharma YK. Clinicoepidemiological study of different types of warts. Dermatol Res Pract. 2016;2016:1–4.
   Google Scholar
• Theng TSC, Goh BK, Chong WS, et al. Viral warts in children seen at a tertiary referral centre. Ann Acad Med Singapore. 2004;33:53–56.
   PubMed Web of Science ®Google Scholar
• Park BS, Lee JO. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med. 2013;45:e66. ‏
   PubMed Web of Science ®Google Scholar
• Daud II, Scott ME, Ma Y, et al. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer. 2011;128:879–886. ‏
   PubMed Web of Science ®Google Scholar
• Kim JH, Key EY, Song MJ, et al. Toll-like receptor 2 gene polymorphisms in Korean women with human papillomavirus-related cervical neoplasia. Acta Obstet Gynecol Scand. 2016;95:829–835.
   PubMed Web of Science ®Google Scholar
• Skevaki C, Pararas M, Kostelidou K, et al. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases. Clin Exp Immunol. 2015;180:165–177.
   PubMed Web of Science ®Google Scholar
• Liu JF, Qu B, Wang XD, et al. Correlation of TLR2 and TLR4 gene polymorphisms with the susceptibility and recurrence of condyloma acuminatum. Zhonghua Nan Ke Xue. 2015;21:708–712.
   PubMedGoogle Scholar
• Zidi S, Sghaier I, Gazouani E, et al. Evaluation of Toll-like receptors 2/3/4/9 gene polymorphisms in cervical cancer evolution. Pathol Oncol Res. 2016;22:323–330.
   PubMed Web of Science ®Google Scholar
• Yu L, Wang L, Li M, et al. Expression of Toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother. 2010;59:1021–1028.
   PubMed Web of Science ®Google Scholar
• Krishnegowda G, Hajjar AM, Zhu J, et al. Induction of proinflammatory responses in macrophages by the glycosylphosphatidyl inositols of Plasmodium falciparum cell signaling receptors, glycosylphosphatidyl inositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem. 2005;280:8606–8616. ‏
   PubMed Web of Science ®Google Scholar
• Sadik NA, Shaker OG, Ghanem HZ, et al. Single nucleotide polymorphism of Toll-like receptor4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients. Arch Virol. 2015;160:2181–2195.
   PubMed Web of Science ®Google Scholar
• Etem EO, Kokcam I, Oguz S, et al. Investigation of association between TLR2 and TlR4 gene polymorphisms and Acne in Turkish subjects. J Harran Univ Med Fac. 2014;11:1–7.
   Google Scholar
• Nofal A, Salah E, Nofal E, et al. Intralesional antigen immunotherapy for the treatment of warts: current concepts and future prospects. Am J Clin Dermatol. 2013;14:253–260. ‏
   PubMed Web of Science ®Google Scholar
• Dasher DA, Burkhart CN, Morrell DS. Immunotherapy for childhood warts. Pediatr Ann. 2009;38:373–379. ‏
   PubMed Web of Science ®Google Scholar
• Böhle A, Büttner H, Jocham D. Primary treatment of condylomata acuminata with viable Bacillus Calmette-Guerin. J Urol. 2001;165:834–836. ‏
   PubMed Web of Science ®Google Scholar
• Thappa DM, Chiramel MJ. Evolving role of immunotherapy in the treatment of refractory warts. Indian Dermatol Online J. 2016;7:364–370.
   PubMedGoogle Scholar
• Perman M, Sterling BJ, Gaspari A. The painful purple digit: an alarming complication of Candida albicans antigen treatment of recalcitrant warts. Dermatitis. 2005;16:38–40. ‏
   PubMed Web of Science ®Google Scholar
• Johnson SM, Roberson PK, Horn TD. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol. 2001;137:451–455. ‏
   PubMed Web of Science ®Google Scholar
• Marei M, Boghdadi G, Tash RM, et al. Efficacy of intralesional Candida antigen immunotherapy in treatment of recalcitrant warts. Zagazig Univ Med J. 2019.
   Google Scholar
• Kim KH, Horn TD, Pharis J, et al. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010;146:1431–1433. ‏
   PubMedGoogle Scholar
• Clifton MM, Johnson SM, Roberson PK, et al. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol. 2003;20:268–271. ‏
   PubMed Web of Science ®Google Scholar
• Sabry HH, Hamed AM, Salem RM, et al. Peripheral blood toll-like receptor 4 correlates response to Candida immunotherapy of warts. Dermatol Ther. 2018;31:e12691. ‏
   PubMed Web of Science ®Google Scholar
• Signore RJ. Candida albicans intralesional injection immunotherapy of warts. Cutis. 2002;70:185–192.
   PubMed Web of Science ®Google Scholar